[1] Tian FM,Zhang L, Zhao HY, et al. An increase in the incidence of hip fractures in Tangshan, China. Osteoporos Int. 2014;25(4): 1321-1325.
[2] Tao ZS, Zhou WS, Tu KK, et al. The effects of combined human parathyroid hormone (1-34) and simvastatin treatment on osseous integration of hydroxyapatite-coated titanium implants in the femur of ovariectomized rats. Injury. 2015; 46(11):2164-2169.
[3] Arita S, Ikeda S, Sakai A, et al. Human parathyroid hormone (1-34) increases mass and structure of the cortical shell, withresultant increase in lumbar bone strength, in ovariectomized rats. J Bone Miner Metab. 2004;22(6):530-540.
[4] Han SL, Wan SL. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials. Int J Clin Pract.2012;66(2):199-209.
[5] Cao Y, Mori S, Mashiba T, et al.Raloxifene, estrogen and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res. 2002; 17 (12): 2237-2246.
[6] Manabe T, Mori S, Mashiba T, et al. Eel calcitonin (elcatonin) suppressed callus remodeling but did not interfere with fracture healing in the femoral fracture model of cynomolgus monkeys. J Bone Miner Metab. 2009;27(3): 295-302.
[7] Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286(5446):1946-1949.
[8] Geesink RG,Hoefnagels NH,Bulstra SK.Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibulas defect.J Bone Joint Surgery.1999; 81(4):710-718.
[9] Sugiyama M,Kodama T, Konishi K,et al.Compacting and simvastatin,but not pravastatin,induce bone morphogenetic protein 2 in human osteosarcoma cell.Biochem Biopsy Res Common.2000;271(13): 688-692.
[10] Song CL, Guo ZQ, Ma QJ, et al. Simvastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells. Biochem Biopsy Res Common.2003;308(3): 458-462.
[11] Oxlund H, Andreassen TT. Simvastatin treatment partially ovariectomy-induced bone loss while increasing cortical bone formation. Bone. 2004;34(4): 609-618.
[12] Chung YS, Lee MD ,Lee SK, et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.J Clin Endocrinol Metab.2000;85(3): 1137-1142.
[13] Wang PS, Solomon DH, Mogun H, et al. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA.2000;283(24):3211-3216.
[14] Maritz FJ, Conradie MM, Hulley PA,et al. Effects of statins on bone mineral density and bone histomorphometry in rodents.Arterioscler Thromb Vasc Biol.2001;21(10):1636-1641
[15] Von Stechow D, Fish S, Yahalom D, et al. Does simvastatin stimulate bone formation in vivo?BMC Musculoskelet Disord. 2003;4: 8
[16] Sehmisch S, Galal R, Kolios L, et al. Effects of low-magnitude, high-frequency mechanical stimulation in the rat osteopenia model. Osteoporos Int. 2009;20(12): 1999-2008.
[17] Khan K, Sharan K, Swarnkar G, et al. Positive skeletal effects of cladrin, a naturally occurring dimethoxydaidzein, in osteopenic rats that were maintained after treatment discontinuation. Osteoporos Int.2013; 24(4):1455-1470.
[18] Luo Y, Zhang L, Wang WY, et al. Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats. Bone.2013; 55(2): 439-448.
[19] Luo Y, Zhang L, Wang WY, et al. The inhibitory effect of salmon calcitonin on intervertebral disc degeneration in an ovariectomized rat model. Eur Spine J.2015; 24(8):1691-1701.
[20] Tian FM, Yang K, Wang WY, et al. Calcitonin suppresses intervertebral disk degeneration and preserves lumbar vertebral bone mineral density and bone strength in ovariectomized rats. Osteoporos Int.2015;26(12):2853-2861.
[21] Khajuria DK, Razdan R, Mahapatra DR. Additive effects of zoledronic acid and propranolol on bone density and biochemical markers of bone turnover in osteopenic ovariectomized rats. Rev Bras Reumatol. 2015;55(2):103-112.
[22] Khan K, Sharan K, Swarnkar G, et al.Positive skeletal effects of cladrin, a naturally occurring dimethoxydaidzein, in osteopenic rats that were maintained after treatment discontinuation. OsteoporosInt. 2013;24(4):1455-1470.
[23] Durão SF, Gomes PS, Colaço BJ, et al. The biomaterial-mediated healing of critical size bone defects in the ovariectomized rat.OsteoporosInt. 2014; 25(5):1535-1545.
[24] Qiu C, Liu X, Wang J, et al.Estrogen increases the transcription of human α2-Heremans-Schmid- glycoprotein by an interplay of estrogen receptor α and activator protein-1. OsteoporosInt. 2014;25(4): 1357-1367.
[25] 郑杰, 张柳, 韩大成.辛伐他汀体内给药部分阻止大鼠去卵巢导致的骨丢失[J]. 中国骨质疏松杂志, 2008, 14(9): 654-658.
[26] 卜建龙, 徐亮, 张品一, 等. 不同用药方案阿仑磷酸钠治疗老年性骨质疏松症的临床疗效分析[J]. 中国骨质疏松杂志, 2014, 20(2): 181-184+224.
[27] Haddad PT, Salazar M, Hernandes L. Histomorphometry of the organic matrix of the femur in ovariectomized rats treated with sodium alendronate. Rev Bras Ortop.2014;50(1):100-104.
[28] Khan A,Dubois S,Khan AA, et al.A randomized, double-blind, placebo-controlled study to evaluate the effects of alendronate on bone mineral density and bone remodelling in perimenopausal women with low bone mineral density. J Obstet Gynaecol Can. 2014; 36(11): 976-982
[29] Hassler N, Gamsjaeger S, Hofstetter B, et al. Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties. Osteoporos Int. 2015; 26 (1):339-352.
[30] Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016; 374 (3): 254-262..
[31] Rugpolmuang L, Waikakul S. Effect of a Short-Term Treatment with Once-A-Week Medication of Alendronate 70 Mg on Bone Turnover Markers in Postmenopausal Women with Osteoporosis. J Med Assoc Thai. 2015; 98 Suppl 8:S70-75.
[32] Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155-170.
[33] Serrano AJ, Begoña L, Anitua E, et al. Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis. 2013; 29(12): 1005-1014.
[34] Paggiosi MA, Peel N, McCloskey E, et al. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study. Osteoporos Int. 2014; 25(12): 2729-2741.
[35] Naylor KE, Jacques RM, Paggiosi M, et al. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int. 2016; 27(1): 21-31.
[36] Gossiel F, Hoyle C, McCloskey EV, et al. The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study. Bone. 2016; 92:94-99.
[37] Li M, Zhang ZL, Liao EY, et al. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis. Menopause. 2013; 20(1): 72-78.
[38] Eiken P, Vestergaard P. Treatment of osteoporosis after alendronate or risedronate. Osteoporos Int. 2016; 27(1): 1-12.
[39] Amugongo SK,Yao W,Jia J,et al.Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats. Bone. 2014; 67: 257-268.
[40] Kalea?as?o?lu F,Olcay E,Olgaç V. Statin-induced calcific Achilles tendinopathy in rats: comparison of biomechanical and histopathological effects of simvastatin, atorvastatin and rosuvastatin. Knee Surg Sports Traumatol Arthrosc,2015 Aug 15. [Epub ahead of print] |